• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Brookline Capital Acquisition Corp. (Amendment)

    8/1/22 3:48:29 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials
    Get the next $BCAC alert in real time by email
    SC 13G/A 1 lf_sc13gz.htm SCHEDULE 13G Schedule 13G

     

    OMB APPROVAL

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    OMB Number:3235-0145 

    Expires:Febuary 28, 2009 

    Estimated average burden
    hours per response ....10.4

     

     

    SCHEDULE 13G

    Under the Securities and Exchange Act of 1934

    (Amendment No.       1          )*

     

    Brookline Capital Acquisition Corp.

    (Name of Issuer)

     

    Common stock, par value $ 0.0001

    (Title of Class of Securities)

     

    11374E104

    (CUSIP Number)

     

     

    August 1, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o  Rule 13d-1(b)

    ý  Rule 13d-1(c)

    o  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1


     

    CUSIP No.    11374E104

    1.Names of Reporting Persons. 

    I.R.S. Identification Nos. of above persons (entities only). 

    Feis Equities LLC 

    2.Check the Appropriate Box if a Member of a Group 

    (a)o 

    (b)o 

    3.SEC Use Only 

    4.Citizenship or Place of OrganizationState of Illinois 

    Number of Shares Beneficially Owned by Each Reporting Person With

    5.Sole Voting Power0 

    6.Shared Voting Power0 

    7.Sole Dispositive Power0 

    8.Shared Dispositive Power0 

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 

    0 

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      o 

    11.Percent of Class Represented by Amount in Row (9) 

    0.00% 

    12.Type of Reporting Person (See Instructions) 

    OO-Limited Liability Company 


    2


     

    CUSIP No.    11374E104

    1.Names of Reporting Persons. 

    I.R.S. Identification Nos. of above persons (entities only). 

    Lawrence M. Feis 

    2.Check the Appropriate Box if a Member of a Group 

    (a)o 

    (b)o 

    3.SEC Use Only 

    4.Citizenship or Place of OrganizationU.S.A. 

    Number of Shares Beneficially Owned by Each Reporting Person With

    5.Sole Voting Power0 

    6.Shared Voting Power0 

    7.Sole Dispositive Power0 

    8.Shared Dispositive Power0 

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 

    0 

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      o 

    11.Percent of Class Represented by Amount in Row (9)  

    0.00% 

    12.Type of Reporting Person (See Instructions) 

    IN 


    3


     

    Item 1.

    The name and address of the principal executive offices of the Issuer are:

    Brookline Capital Acquisition Corp.

    280 Park Avenue

    Suite 43W

    New York, New York 10017

    Item 2.

    This statement on Schedule 13G is being filed by:

    (a) Name of Person Filing 

     

    (i)Feis Equities LLC 

    (ii)Lawrence M. Feis 

     

     

     

     

     

    (b)Address: 

    The address of the business office of each of the Reporting Persons is:

     

    20 North Wacker Drive

    Suite 2115

    Chicago, Illinois  60606

     

     

     

     

     

    (c)Citizenship/Place: 

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated hereto by reference for each Reporting Person.

     

    (d)Title of Class of Securities: 

    Common stock, par value $ 0.0001 (the “Shares”)

     

    (e)CUSIP Number: 

     

    11374E104

     

     

     


    4


    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a)oBroker or dealer registered under section 15 of the Act (15 U.S.C. 78o). 

    (b)oBank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). 

    (c)oInsurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). 

    (d)oInvestment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). 

    (e)oAn investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); 

    (f)oAn employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); 

    (g)oA parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 

    (h)oA savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); 

    (i)oA church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); 

    (j)oGroup, in accordance with §240.13d-1(b)(1)(ii)(J). 

    Item 4.  Ownership

     

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page for each Reporting Person and incorporated by reference herein.

     

    The percentage set forth in row 11 of the cover page for each Reporting Person is based on 6,746,092 shares of Common stock outstanding as of May 20,2022, as reported by the Issuer in its 10-Q filing for the period ended March 31, 2022, filed with the Securities and Exchange Commission on May 23, 2022.


    5


     

    Item 5.  Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ý

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

    Item 8.  Identification and Classification of Members of the Group

    Not applicable.

    Item 9.  Notice of Dissolution of Group

    Not applicable.

    Item 10.  Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    6


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:August 1, 2022 

     

     

     

     

    Date:August 1, 2022 

     

    FEIS EQUITIES LLC

    By:/s/ Lawrence M. Feis 

                Managing Member LLC

     

     

    LAWRENCE M. FEIS

    By:/s/ Lawrence M. Feis 

     


    7


     

     

    EXHIBIT INDEX

     

    Ex.

     

    Page No.

     

     

     

    A

    Joint Filing Agreement

    9


    8


     

    JOINT FILING AGREEMENT

     

    The undersigned hereby agree that the statement on Schedule 13G with respect to the Common stock of Brookline Capital Acquisition Corp. dated as of August 1, 2022 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

    FEIS EQUITIES LLC 

    By:/s/ Lawrence M. Feis 

    Managing Member LLC 

     

     

    LAWRENCE M. FEIS 

    By:/s/ Lawrence M. Feis 

     

    Date:  August 1, 2022


    9

    Get the next $BCAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BCAC
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by Brookline Capital Acquisition Corp.

    S-1/A - Brookline Capital Acquisition Corp II (0002102072) (Filer)

    2/10/26 5:07:10 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form 10-Q filed by Brookline Capital Acquisition Corp.

    10-Q - Apexigen, Inc. (0001814140) (Filer)

    11/14/22 5:13:36 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Brookline Capital Acquisition Corp. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Other Events, Financial Statements and Exhibits

    8-K - Apexigen, Inc. (0001814140) (Filer)

    11/14/22 4:07:21 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Wong Amy covered exercise/tax liability with 2,851 shares, decreasing direct ownership by 17% to 13,637 units

    4 - Apexigen, Inc. (0001814140) (Issuer)

    12/19/22 5:57:25 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Sarena Francis Willard covered exercise/tax liability with 6,916 shares, decreasing direct ownership by 17% to 33,084 units

    4 - Apexigen, Inc. (0001814140) (Issuer)

    12/19/22 5:49:39 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Hsu Frank J. covered exercise/tax liability with 4,323 shares, decreasing direct ownership by 17% to 20,677 units

    4 - Apexigen, Inc. (0001814140) (Issuer)

    12/19/22 5:41:54 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apexigen to Participate in the Brookline Capital Markets Newport Symposium

    SAN CARLOS, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that Apexigen's Management will participate in the Brookline Capital Markets Newport Symposium, to be held in Newport, Rhode Island on Monday, July 18, 2022. Brookline Capital Markets Newport SymposiumFormat: Apexigen presentation and 1-on-1 meetingsDate: Monday, July 18, 2022Location: Newport, Rhode Island Please contact your Brookline Capital Markets sales representative for additional information. About Apexigen, Inc.Apexigen is a clinical-st

    7/11/22 8:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Apexigen Announces Board Appointment and New Chair

    SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp

    6/29/22 4:05:00 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Apexigen Appoints William Duke as Chief Financial Officer

    SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon

    6/8/22 8:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Leadership Updates

    Live Leadership Updates

    View All

    Apexigen Announces Board Appointment and New Chair

    SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp

    6/29/22 4:05:00 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Apexigen Appoints William Duke as Chief Financial Officer

    SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon

    6/8/22 8:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Financials

    Live finance-specific insights

    View All

    Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company

    - Healthcare institutional investors and insiders commit $15 million through private investment in public equity ("PIPE") - - Lincoln Park Capital has committed to purchase up to $50 million of common stock - - Proceeds to advance the Phase 2 development of Apexigen's lead asset, sotigalimab, a CD40 agonist antibody with first-in-class and best-in-class potential - - Merger expected to be completed in July 2022; combined company expected to be listed on Nasdaq under the ticker symbol "APGN" - - Joint investor conference call to discuss the proposed transaction today, Friday, March 18, 2022 at 8:30 a.m. ET - SAN CARLOS, Calif. and NEW YORK, March 18, 2022

    3/18/22 6:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Brookline Capital Acquisition Corp.

    SC 13G - Apexigen, Inc. (0001814140) (Subject)

    8/8/22 12:18:48 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by Brookline Capital Acquisition Corp. (Amendment)

    SC 13G/A - Brookline Capital Acquisition Corp. (0001814140) (Subject)

    8/1/22 3:48:29 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G filed by Brookline Capital Acquisition Corp.

    SC 13G - Brookline Capital Acquisition Corp. (0001814140) (Subject)

    4/13/22 3:32:08 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials